More broadly, there is a clear need for high-quality trials to evaluate the long-term efficacy, safety, and cost-effectiveness of GLP-1 agonists, both as monotherapy and in combination with other treatments for patients with OSA. Here, GLP1R is linked to obstructive sleep apnea syndrome.